Introduction
The rapid expansion of genetic testing has introduced a significant clinical hurdle: the identification of "variants of uncertain significance" (VUS). While computational models attempt to predict pathogenicity based on evolutionary conservation, they often struggle with proteins containing intrinsically disordered regions. This study addresses a novel VUS (P93S) in the ANXA11 gene, identified in a family presenting with corticobasal syndrome (CBS). By employing a multi-modal biological validation pipeline using human induced pluripotent stem cells (iPSCs), researchers have confirmed the pathogenicity of this variant, expanding the known clinical spectrum of ANXA11 mutations and revealing a complex interplay between neuronal transport and microglial immune dysregulation.
Methods
To investigate the P93S variant, the researchers utilized a comprehensive suite of clinical and molecular tools. They first performed clinical profiling of the affected kindred using MRI and cerebrospinal fluid (CSF) analysis. To validate the variant's functional impact, they engineered human iPSCs to differentiate into cortical-like neurons and microglia. These cells were then modified via lentiviral overexpression to express either wildtype or P93S mutant ANXA11.
Functional assays included live-cell imaging to monitor the colocalization of ANXA11 with lysosomes, and RNAscope to quantify RNA delivery to distal neurites. To assess the downstream impact on RNA metabolism, the team used immunocytochemistry to track TDP-43 localization and developed a novel Hybridization Chain Reaction Fluorescence In Situ Hybridization (HCR FISH) method to detect cryptic exons. Finally, single-cell RNA sequencing (scRNAseq) and mass spectrometry-based proteomics were conducted to capture the global cellular response to the mutation.
Results
Expanding the Clinical Spectrum
The study successfully linked ANXA11 mutations to clinically diagnosed corticobasal syndrome, a finding supported by queries of large neurodegenerative disease databases. This establishes CBS as a distinct phenotype within the ANXA11 clinical spectrum, which previously centered on amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Neuronal Transport Breakdown and TDP-43 Pathology
In iPSC-derived neurons, the P93S mutation severely disrupted the protein's normal function. Live-cell imaging revealed a 75% decrease in the colocalization of ANXA11 with lysosomes, a critical step for RNA granule transport. This tethering failure led to a 15% reduction in axonal beta-actin RNA.
Furthermore, the mutation triggered hallmark features of TDP-43 proteinopathy. Mutant neurons exhibited a significant loss of nuclear TDP-43, with mean intensity dropping from 0.386 in controls to 0.185. This loss of nuclear function resulted in a 3.5-fold increase in STMN2 cryptic exons and a 37% increase in UNC13A cryptic transcripts—abnormal splicing products that are highly specific markers of TDP-43 dysfunction.
Microglial Immune Dysregulation
One of the most striking findings was the profound impact of the ANXA11 mutation on microglia. While ANXA11 is well-known for its role in neuronal axonal transport, multiomic analysis showed that the P93S variant caused more extensive transcriptomic and proteomic changes in microglia than in neurons. Proteomics identified 684 differentially expressed proteins in microglia compared to 434 in neurons. These changes were primarily associated with innate immune responses, lipid metabolism, and interferon signaling pathways, suggesting that neuroinflammation is a primary driver of the disease rather than a secondary response.
Discussion
This research highlights a critical limitation of current in silico prediction tools. The P93S mutation resides in a "low complexity domain" (LCD) of ANXA11. Because these regions are intrinsically disordered and often lack conservation across species, standard algorithms frequently misclassify pathogenic mutations in these domains as benign. The structural rigidity provided by prolines in these domains is essential; replacing a proline with a serine (P93S) disrupts the protein's ability to facilitate RNA transport.
The study also underscores the importance of considering non-neuronal cells in neurodegenerative disease. The significant immune signature observed in microglia suggests that ANXA11-related pathologies may share mechanisms with autoimmune conditions, such as sarcoidosis, where ANXA11 has also been implicated.
Conclusion
By integrating clinical data with iPSC-derived cellular models and multiomics, this study provides a robust framework for the biological validation of VUS. The findings definitively classify the ANXA11 P93S variant as pathogenic, expand the clinical range of ANXA11 mutations to include CBS, and implicate both neuronal transport failure and microglial dysfunction in the disease's pathophysiology. This approach offers a scalable model for improving variant annotation and diagnostic accuracy in the era of genomic medicine.
Summary updated